Roche reported MabThera/Rituxan sales of CHF 1.9 billion (approximately $1.95 billion) in the first quarter of 2017, up 4% on Q1 2016 sales.
Latest posts by CHF Editor (see all)
- BRIEF-Novavest Real Estate H1 net rental income up 52% at CHF 7.7 mln - August 18, 2017
- USD/CHF extends gains above 0.9700 as CHF consolidates losses https://t.co/9dtzqlOTiE #USDCHF - August 18, 2017
- Flows: EUR/CHF, USD/CHF, USD/JPY – sentiment still uncertain into the close #forex #fx #mkt https://t.co/LHTypMCKIs - August 18, 2017